184 related articles for article (PubMed ID: 18684695)
1. Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone.
Kim BS; Kim DW; Im SA; Kim CW; Kim TY; Yoon SS; Heo DS; Bang YJ; Park S; Kim BK; Kim NK
Ann Oncol; 2009 Jan; 20(1):121-8. PubMed ID: 18684695
[TBL] [Abstract][Full Text] [Related]
2. Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL).
Kim M; Kim TM; Kim KH; Keam B; Lee SH; Kim DW; Lee JS; Jeon YK; Kim CW; Heo DS
Ann Hematol; 2015 Mar; 94(3):437-44. PubMed ID: 25300500
[TBL] [Abstract][Full Text] [Related]
3. First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/- radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma.
Lee KW; Yun T; Kim DW; Im SA; Kim TY; Yoon SS; Heo DS; Bang YJ; Park S; Kim BK; Kim NK
Leuk Lymphoma; 2006 Jul; 47(7):1274-82. PubMed ID: 16923557
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of ifosfamide, methotrexate, etoposide, and prednisolone for previously untreated stage I/II extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial of the Korean Cancer Study Group.
Kim TM; Kim DW; Kang YK; Chung J; Song HS; Kim HJ; Kim BS; Lee JS; Kim H; Yang SH; Yuh YJ; Bae SH; Hyun MS; Jeon YK; Kim CW; Heo DS
Oncologist; 2014 Nov; 19(11):1129-30. PubMed ID: 25280488
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia.
Yamaguchi M; Suzuki R; Kwong YL; Kim WS; Hasegawa Y; Izutsu K; Suzumiya J; Okamura T; Nakamura S; Kawa K; Oshimi K
Cancer Sci; 2008 May; 99(5):1016-20. PubMed ID: 18294294
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type.
Kim HJ; Ock CY; Kim TM; Lee SH; Lee JY; Jung SH; Cho YS; Kim M; Keam B; Kim DW; Kim IH; Heo DS
Cancer Res Treat; 2018 Jul; 50(3):670-680. PubMed ID: 28675023
[TBL] [Abstract][Full Text] [Related]
7. SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type.
Wei L; Wang L; Cong J; Yang L; Ye J; Li X; Yao N; Yang J; Wang J
Leuk Res; 2020 Sep; 96():106422. PubMed ID: 32721642
[TBL] [Abstract][Full Text] [Related]
8. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group.
Kwong YL; Kim WS; Lim ST; Kim SJ; Tang T; Tse E; Leung AY; Chim CS
Blood; 2012 Oct; 120(15):2973-80. PubMed ID: 22919026
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study.
Kim SJ; Kim K; Kim BS; Kim CY; Suh C; Huh J; Lee SW; Kim JS; Cho J; Lee GW; Kang KM; Eom HS; Pyo HR; Ahn YC; Ko YH; Kim WS
J Clin Oncol; 2009 Dec; 27(35):6027-32. PubMed ID: 19884539
[TBL] [Abstract][Full Text] [Related]
10. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
11. High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed/refractory extranodal natural killer/T cell lymphoma: a retrospective study.
Ding H; Chang J; Liu LG; Hu D; Zhang WH; Yan Y; Ma LY; Li ZC; Ma YJ; Hao SG; Tao R
Int J Hematol; 2015 Aug; 102(2):181-7. PubMed ID: 25997870
[TBL] [Abstract][Full Text] [Related]
12. Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.
Oh D; Ahn YC; Kim SJ; Kim WS; Ko YH
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):677-83. PubMed ID: 26461010
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.
Yamaguchi M; Kwong YL; Kim WS; Maeda Y; Hashimoto C; Suh C; Izutsu K; Ishida F; Isobe Y; Sueoka E; Suzumiya J; Kodama T; Kimura H; Hyo R; Nakamura S; Oshimi K; Suzuki R
J Clin Oncol; 2011 Nov; 29(33):4410-6. PubMed ID: 21990393
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial in Northwest China.
Liang R; Gao GX; Chen JP; Wang JS; Wang XM; Zeng Y; Bai QX; Zhang T; Yang L; Dong BX; Gu HT; Shu MM; Hao CX; Wang JH; Zhang N; Chen XQ
Hematol Oncol; 2017 Dec; 35(4):619-629. PubMed ID: 27723108
[TBL] [Abstract][Full Text] [Related]
15. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
Arellano-Rodrigo E; López-Guillermo A; Bessell EM; Nomdedeu B; Montserrat E; Graus F
Eur J Haematol; 2003 Apr; 70(4):219-24. PubMed ID: 12656744
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008).
Yoon DH; Kim SJ; Jeong SH; Shin DY; Bae SH; Hong J; Park SK; Yhim HY; Yang DH; Lee H; Kang HJ; Lee MH; Eom HS; Kwak JY; Lee JH; Suh C; Kim WS
Oncotarget; 2016 Dec; 7(51):85584-85591. PubMed ID: 27542213
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type.
Ito Y; Kimura H; Maeda Y; Hashimoto C; Ishida F; Izutsu K; Fukushima N; Isobe Y; Takizawa J; Hasegawa Y; Kobayashi H; Okamura S; Kobayashi H; Yamaguchi M; Suzumiya J; Hyo R; Nakamura S; Kawa K; Oshimi K; Suzuki R
Clin Cancer Res; 2012 Aug; 18(15):4183-90. PubMed ID: 22675173
[TBL] [Abstract][Full Text] [Related]
18. Etoposide, ifosfamide and methotrexate combination chemotherapy in patients with aggressive non-Hodgkin's lymphoma after failure of the LNH 84 regimen.
Herbrecht R; Ortiz S; Damonte JC; Liu KL; Maloisel F; Dufour P; Bergerat JP; Oberling F
Hematol Oncol; 1991; 9(4-5):253-7. PubMed ID: 1720760
[TBL] [Abstract][Full Text] [Related]
19. Etoposide, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen.
Herbrecht R; Damonte JC; Dufour P; Maloisel F; Liu KL; Ortiz S; Bergerat JP; Oberling F
Semin Oncol; 1992 Feb; 19(1 Suppl 1):7-10. PubMed ID: 1384135
[TBL] [Abstract][Full Text] [Related]
20. A study of gemcitabine, l-asparaginase, ifosfamide, dexamethasone and etoposide chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type.
Ji J; Liu T; Xiang B; Liu W; He C; Chen X; Li J; Chang H; Dai Y; Dong T
Leuk Lymphoma; 2014 Dec; 55(12):2955-7. PubMed ID: 24679007
[No Abstract] [Full Text] [Related]
[Next] [New Search]
